

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Oncology

Manuscript NO: 88756

Title: Computed tomography radiogenomics: A potential tool for prediction of

molecular subtypes in gastric stromal tumor

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 04732834 Position: Peer Reviewer Academic degree: MD, PhD

Professional title: Director, Full Professor, Surgical Oncologist

Reviewer's Country/Territory: Romania

Author's Country/Territory: China

Manuscript submission date: 2023-10-08

Reviewer chosen by: Huo Liu

Reviewer accepted review: 2023-12-21 17:35

Reviewer performed review: 2023-12-21 18:08

Review time: 1 Hour

	[] Grade A: Excellent [] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of this manuscript	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair [] Grade D: No creativity or innovation



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** office@baishideng.com https://www.wjgnet.com

Scientific significance of the	[] Grade A: Excellent [] Grade B: Good [Y] Grade C: Fair
conclusion in this manuscript	[] Grade D: No scientific significance
	[Y] Grade A: Priority publishing [] Grade B: Minor language
Language quality	polishing [] Grade C: A great deal of language polishing []
	Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority)
	[Y] Minor revision [] Major revision [] Rejection
Re-review	[]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous
	Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The paper is beyond my expertise as far as statistical approah and radiomics studies. To my understanding you try to predict the mutation based on preoperative CT scan, but I do not understand how this will be reflected in a benefit for patients. With AUC curves of 0.7-0.8 you have a relatively good prediction but I fail to understand the clinical benefit. Your scoring system takes into account CD34 and Kit expression ,meaning you have a sample of tumor on which you can generate genetic analysis. I decline my capacity to judge you paper and ask the editor to send it to another reviewer.